A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2004
10/21/2004	CA2522214A1 4-phenyl-piperidine compounds and their use as modulators of opioid receptors
10/21/2004	CA2522115A1 A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid
10/21/2004	CA2522023A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
10/21/2004	CA2521902A1 Pharmaceutical combination comprising eletriptan and sodium bicarbonate
10/21/2004	CA2521879A1 Process for resolving amines that are useful for the treatment of disorders associated with insulin resistance syndrome
10/21/2004	CA2521875A1 Calcium channel blockers comprising two benzhydril moieties
10/21/2004	CA2521830A1 Heteroaromatic pentacyclic compound and medicinal use thereof
10/21/2004	CA2521788A1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
10/21/2004	CA2521713A1 Anti-fungal peptidomimetics
10/21/2004	CA2521692A1 Modified acacia and use thereof
10/21/2004	CA2521685A1 Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues
10/21/2004	CA2521656A1 Treatment of epilepsy
10/21/2004	CA2521632A1 Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug
10/21/2004	CA2521606A1 Novel methods for the treatment of inflammatory diseases
10/21/2004	CA2521603A1 Stable carprofen composition
10/21/2004	CA2521429A1 Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care
10/21/2004	CA2521416A1 Polyamine compounds for treating chemokine receptor mediated diseases
10/21/2004	CA2521407A1 Polymeric drug agents for the treatment of fibrotic disorders
10/21/2004	CA2521402A1 Pectate lyases, nucleic acids encoding them and methods for making and using them
10/21/2004	CA2521399A1 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
10/21/2004	CA2521396A1 Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
10/21/2004	CA2521380A1 Synbiotic combination
10/21/2004	CA2521348A1 Processes for the preparation of n-((((pyridinyloxy)-phenylamino) quinazolinyl)-allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
10/21/2004	CA2521330A1 Calcium channel inhibitors comprising benzhydril spaced from piperazine
10/21/2004	CA2521201A1 Substituted pyrazoles for use in the prophylaxis or treatment of a disease which can be influenced by the binding of the substitued pyrazoles to 5ht receptors
10/21/2004	CA2521186A1 Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists with antidepressant and anxiolytic activity
10/21/2004	CA2521184A1 Novel compounds and compositions as protein kinase inhibitors
10/21/2004	CA2521000A1 Preventive and/or therapeutic agent for neuropathic pain
10/21/2004	CA2520962A1 Method and apparatus for system management using codebook correlation with symptom exclusion
10/21/2004	CA2520865A1 Zwitterionic immunomodulators for the treatment of asthma and allergy
10/21/2004	CA2520855A1 Imidazopyridine derivatives as melanocortin receptor agonists
10/21/2004	CA2520766A1 Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
10/21/2004	CA2520763A1 Improved inhibitors for the soluble epoxide hydrolase
10/21/2004	CA2520611A1 Hydroxamic acid compounds and methods of use thereof
10/21/2004	CA2520468A1 Treating or preventing hot flashes using prodrugs of gaba analogs
10/21/2004	CA2520452A1 Sapphyrins and uses thereof
10/21/2004	CA2520347A1 Prostaglandin compositions and their use for the treatment of vasospasm
10/21/2004	CA2520114A1 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
10/21/2004	CA2519882A1 Novel crystals of fluorobenzamide derivative
10/21/2004	CA2519794A1 Novel carbapenem compounds
10/21/2004	CA2519380A1 Compositions and method for treating microbial and parasitic infections in cattle and other animals
10/21/2004	CA2519379A1 Method of treating lower urinary tract disorders
10/21/2004	CA2518916A1 Pi-3 kinase inhibitor prodrugs
10/21/2004	CA2517833A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
10/21/2004	CA2517336A1 Purin-6-one-derivatives
10/21/2004	CA2505848A1 Highly pure bases of 3,3-diphenyl propylamine monoesters
10/21/2004	CA2488224A1 Irna conjugates
10/20/2004	EP1469084A2 Polymorphisms in the human KDR gene
10/20/2004	EP1469075A1 Gene-therapy for solid tumors, papillomas and warts
10/20/2004	EP1469072A2 Means and methods for diagnosing and treating affective disorders
10/20/2004	EP1469011A1 Hemoglobin conjugates
10/20/2004	EP1469009A2 Compositions and methods for non-parenteral delivery of oligonucleotides
10/20/2004	EP1469008A1 Method of preparing a non-pharmaceutical grade clarithromycin
10/20/2004	EP1468999A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
10/20/2004	EP1468998A1 Crystalline monohydrate of Tiotropium bromide and process for its preparation
10/20/2004	EP1468996A1 Indole derivatives for the treatment of CNS disorders
10/20/2004	EP1468995A1 MPTP affinity labels
10/20/2004	EP1468991A1 Imides as PDE III, PDE IV and TNF inhibitors
10/20/2004	EP1468990A1 Piperazine derivative
10/20/2004	EP1468985A1 A process for the preparation of gabapentin free from inorganic acids anions
10/20/2004	EP1468699A1 Mycobactericidal Disinfection Agent
10/20/2004	EP1468698A2 Human quinone reductase 2 conjugates for adept and gdept
10/20/2004	EP1468697A1 Compositions containing piperacillin and tazobactam useful for injection
10/20/2004	EP1468696A1 Combinations of epinastine and antiphlogisitcs as new pharmaceutical compositions for the treatment of skin diseases
10/20/2004	EP1468693A2 Use of 2,6-di -alkyl-4-silyl-phenols for treating diabetes mellitus
10/20/2004	EP1468692A2 Use of 2,6-di-alkyl-4-silyl-phenols for treating xanthoma
10/20/2004	EP1468691A1 Use of bisphosphonates in the treatment of vascular restenosis
10/20/2004	EP1468690A1 Use of estrogens for the treatment of infertility in male mammals
10/20/2004	EP1468689A1 2-methyl-thieno-benzodiazepine formulation
10/20/2004	EP1468688A2 Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
10/20/2004	EP1468687A1 Compounds for the treatment of cancer
10/20/2004	EP1468686A2 S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
10/20/2004	EP1468685A2 Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
10/20/2004	EP1468684A1 Sigma receptor binder containing indanone derivative
10/20/2004	EP1468683A2 Pharmaceutical composition for oral use with angiotensin-II-antagonistic activity and method of preparing it
10/20/2004	EP1468682A1 Therapeutic combinations comprising amlodipine and atorvastatin
10/20/2004	EP1468681A1 Fenofibrate pharmaceutical composition with a higher bioavailability and its manufacturing process
10/20/2004	EP1468680A2 Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
10/20/2004	EP1468679A2 Controlled release formulation containing tramadol
10/20/2004	EP1468678A1 Pharmaceutical foam aerosol comprising Dexpanthenol
10/20/2004	EP1468677A2 An antireflux syrup
10/20/2004	EP1468676A2 Poly (vinyl alcohol) cryogel
10/20/2004	EP1468110A2 Molecular signatures of commonly fatal carcinomas
10/20/2004	EP1468091A2 Transmembrane protein
10/20/2004	EP1468082A1 Crystal structure of phosphodiesterase 5 and use thereof
10/20/2004	EP1468019A2 Secreted protein
10/20/2004	EP1468018A2 Leptin proteins
10/20/2004	EP1468011A1 Biomolecule transduction motif sim-2-btm and the use thereof
10/20/2004	EP1468008A2 MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) PROMOTER POLYMORPHISM IN INFLAMMATORY DISEASE
10/20/2004	EP1468005A2 Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
10/20/2004	EP1468003A2 Phosphinic pseudo-peptide derivatives
10/20/2004	EP1467999A1 Oxothieno[3,2-b]pyridinecarboxamides as antiviral agents
10/20/2004	EP1467998A1 Tetracyclic heterocompounds as estrogen receptor modulators
10/20/2004	EP1467997A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
10/20/2004	EP1467996A1 Pyrimidotriazines as phosphatase inhibitors
10/20/2004	EP1467995A2 Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
10/20/2004	EP1467994A1 Pteridine derivatives, method for the production thereof, and use thereof
10/20/2004	EP1467993A1 Method for producing scopine esters
10/20/2004	EP1467992A1 Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones
10/20/2004	EP1467991A1 Prucalopride-n-oxide

1 ... 4919 4920 4921 4922 4923 4924 4925 4926 4927 4928 4929 4930 4931 4932 4933 4934 4935 4936 4937 4938 4939 ... 7860